Abstract: The aim of this research was to assess the clinical utility of Eosinophil Derived Neurotoxin (EDN) and immunoglobulin E (IgE) as biomarkers for bronchial asthma evaluation as regard type (atopic vs non atopic) and severity. The study included 39 atopic asthmatic patients (group 1), 31 non atopic asthmatic patients (group 2) and 20 age and sex matched controls (group 3) with their age ranged from 7-17 years. Eosinophil count, serum level of immunoglobulin E (IgE), EDN and spirometry were done for all cases. A positive correlation between EDN and eosinophil count was found (r = 0.423 and p<0.01) and between serum EDN and IgE (r = 0.401 and p<0.03). Serum EDN and IgE levels showed statistically significant difference between group 1 and 2 (p<0.001 and 0.01, respectively) and between group 1 and 3 (p<0.001 and 0.003, respectively), but no statistically significant difference was found between group 2 and 3 for both parameters. No correlations were found between EDN or IgE and FEV1 (%) predicted. EDN level showed a statistically significant difference between groups when patients classified into 4 groups based on symptoms and drug use in comparison to IgE which showed no statistically significant difference between the same groups. The study suggests that serum EDN may be superior to IgE as a biomarker for evaluation of asthma regarding its type and severity.